Biosimilar medicines: Why the science matters

被引：6

作者：

Gonzalez-Quevedo, Rosa ^{[1
]}

Wolff-Holz, Elena ^{[1
,2
,3
]}

Carr, Melanie ^{[1
]}

Burgos, Juan Garcia ^{[1
]}

机构：

[1] European Med Agcy, Stakeholders & Commun Div, Domenico Scarlattilaan 6, NL-1083 HS Amsterdam, Netherlands

[2] European Med Agcy, Chair Biosimilar Working Party, Paul Ehrlich Str 51-59, D-63225 Langen, Germany

[3] Paul Ehrlich Inst, Fed Inst Vaccines & Biomed, Med Policy Issues, Paul Ehrlich Str 51-59, D-63225 Langen, Germany

来源：

HEALTH POLICY AND TECHNOLOGY | 2020年 / 9卷 / 02期

关键词：

D O I：

10.1016/j.hlpt.2020.03.004

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

引用

页码：132 / 136

页数：5

共 8 条

[1]

[Anonymous], 2019, IQVIA REPORT IMPACT

[2]

European Medicines Agency, 2014, EMA1684022014

[3]

European Medicines Agency, OV BIOS MED

[4]

European Medicines Agency, INF GUID BIOS HEALTH

[5] Interchangeability of Biosimilars: A European Perspective [J].

Kurki, Pekka ;

van Aerts, Leon ;

Wolff-Holz, Elena ;

Giezen, Thijs ;

Skibeli, Venke ;

Weise, Martina .

BIODRUGS, 2017, 31 (02) :83-91

[6] Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice [J].

Vermeer, Niels S. ;

Giezen, Thijs J. ;

Zastavnik, Sofia ;

Wolff-Holz, Elena ;

Hidalgo-Simon, Ana .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (04) :962-969

[7] Biosimilars: what clinicians should know [J].

Weise, Martina ;

Bielsky, Marie-Christine ;

De Smet, Karen ;

Ehmann, Falk ;

Ekman, Niklas ;

Giezen, Thijs J. ;

Gravanis, Iordanis ;

Heim, Hans-Karl ;

Heinonen, Esa ;

Ho, Kowid ;

Moreau, Alexandre ;

Narayanan, Gopalan ;

Kruse, Nanna A. ;

Reichmann, Gabriele ;

Thorpe, Robin ;

van Aerts, Leon ;

Vleminckx, Camille ;

Wadhwa, Meenu ;

Schneider, Christian K. .

BLOOD, 2012, 120 (26) :5111-5117

[8] Evolution of the EU Biosimilar Framework: Past and Future [J].

Wolff-Holz, Elena ;

Tiitso, Klara ;

Vleminckx, Camille ;

Weise, Martina .

BIODRUGS, 2019, 33 (06) :621-634

← 1 →